
    
      This is a Phase II randomized, double-blind, placebo-controlled study for dose selection in
      postmenopausal women with moderate to severe VMS, defined as follows:

        -  Moderate: sensation of heat with sweating, able to continue activity

        -  Severe: sensation of heat with sweating, causing cessation of activity This study is
           comprised of a screening period, a run-in period and a 12-week double-blind treatment
           period.
    
  